Seer Readies $150 Million IPO Plan

Seer (SEER) has filed to raise $150 million from the sale of its Class A common stock in an IPO, according to an amended registration statement.

Redwood City, California-based Seer was founded to develop instruments to analyze proteins for basic research and discovery.

Management is headed by co-founder and CEO Omid Farokhzad, M.D., who was previously Professor at Harvard Medical School and co-founded BIND Therapeutics, Selecta Biosciences and Tarveda Therapeutics.

Below is a brief overview video of proteomics research:

Source: Sensu Film

The firm is developing what it calls the Proteograph Product Suite, ‘which will leverage our proprietary engineered nanoparticle [NP] technology to provide unbiased, deep, rapid and large-scale access across the proteome.’

Investors in the firm have invested at least $167 million and include Maverick Capital, Invus Public Equities, aMoon Fund, Fidelity, Emerson Collective and T. Rowe Price.

According to a 2016 market research report by Grand View Research,

Read More

Seer Begins $150 Million U.S. IPO Plan

Seer (SEER) intends to raise $150 million in an IPO of its Class A common stock, according to an S-1 registration statement.

Redwood City, California-based Seer was founded to develop instruments to analyze proteins for basic research and discovery.

Management is headed by co-founder and CEO Omid Farokhzad, M.D., who was previously Professor at Harvard Medical School and co-founded BIND Therapeutics, Selecta Biosciences and Tarveda Therapeutics.

Below is a brief overview video of proteomics research:

Source: Sensu Film

The firm is developing what it calls the Proteograph Product Suite, ‘which will leverage our proprietary engineered nanoparticle [NP] technology to provide unbiased, deep, rapid and large-scale access across the proteome.’

Investors in the firm have invested at least $167 million and include Maverick Capital, Invus Public Equities, aMoon Fund, Fidelity, Emerson Collective and T. Rowe Price.

According to a 2016 market research report by Grand View Research, the global market for

Read More